Ubs Group Ag Pliant Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 230,308 shares of PLRX stock, worth $2.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

230,308

Previous 152,202 51.32%

Holding current value

$2.84 Million

Previous $1.64 Million 57.76%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.52 - $14.35 $821,675 - $1.12 Million	78,106 Added 51.32%	230,308 $2.58 Million
Q2 2024 Aug 13, 2024	SELL	$10.58 - $15.61 $2.25 Million - $3.32 Million	-212,862 Reduced 58.31%	152,202 $1.64 Million
Q1 2024 May 13, 2024	BUY	$14.14 - $19.59 $323,678 - $448,434	22,891 Added 6.69%	365,064 $5.44 Million
Q4 2023 Feb 09, 2024	BUY	$12.85 - $19.15 $917,091 - $1.37 Million	71,369 Added 26.35%	342,173 $6.2 Million
Q3 2023 Nov 09, 2023	BUY	$14.58 - $20.15 $3.9 Million - $5.4 Million	267,780 Added 8855.16%	270,804 $4.7 Million
Q2 2023 Aug 11, 2023	SELL	$18.12 - $30.56 $209,032 - $352,540	-11,536 Reduced 79.23%	3,024 $54,000
Q1 2023 May 12, 2023	BUY	$18.73 - $36.26 $171,660 - $332,322	9,165 Added 169.88%	14,560 $387,000
Q4 2022 Feb 08, 2023	SELL	$17.0 - $25.43 $20,485 - $30,643	-1,205 Reduced 18.26%	5,395 $104,000
Q3 2022 Nov 10, 2022	BUY	$7.67 - $24.23 $23,493 - $74,216	3,063 Added 86.6%	6,600 $138,000
Q2 2022 Aug 10, 2022	BUY	$4.11 - $8.75 $2,260 - $4,812	550 Added 18.41%	3,537 $28,000
Q1 2022 May 16, 2022	SELL	$7.01 - $14.1 $51,411 - $103,409	-7,334 Reduced 71.06%	2,987 $21,000
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.26 $102,957 - $153,219	8,391 Added 434.77%	10,321 $140,000
Q3 2021 Nov 15, 2021	BUY	$16.48 - $28.98 $8,783 - $15,446	533 Added 38.15%	1,930 $32,000
Q2 2021 Aug 13, 2021	BUY	$28.05 - $37.69 $14,053 - $18,882	501 Added 55.92%	1,397 $41,000
Q1 2021 May 12, 2021	SELL	$24.52 - $40.23 $11,843 - $19,431	-483 Reduced 35.03%	896 $35,000
Q4 2020 Feb 11, 2021	SELL	$19.89 - $32.99 $22,495 - $37,311	-1,131 Reduced 45.06%	1,379 $32,000
Q3 2020 Nov 12, 2020	BUY	$21.54 - $29.53 $54,065 - $74,120	2,510 New	2,510 $57,000

Others Institutions Holding PLRX

# of Institutions

168

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account